Please use this identifier to cite or link to this item:
https://observatorio.fm.usp.br/handle/OPI/34245
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor | Sistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSP | |
dc.contributor.author | KAWAHARA, Rebeca | |
dc.contributor.author | RECUERO, Saulo | |
dc.contributor.author | NOGUEIRA, Fabio C. S. | |
dc.contributor.author | DOMONT, Gilberto B. | |
dc.contributor.author | LEITE, Katia R. M. | |
dc.contributor.author | SROUGI, Miguel | |
dc.contributor.author | THAYSEN-ANDERSEN, Morten | |
dc.contributor.author | PALMISANO, Giuseppe | |
dc.date.accessioned | 2020-01-21T14:53:08Z | - |
dc.date.available | 2020-01-21T14:53:08Z | - |
dc.date.issued | 2019 | |
dc.identifier.citation | PROTEOMICS, v.19, n.21-22, Special Issue, article ID 1900174, 12p, 2019 | |
dc.identifier.issn | 1615-9853 | |
dc.identifier.uri | https://observatorio.fm.usp.br/handle/OPI/34245 | - |
dc.description.abstract | The histology-based Gleason score (GS) of prostate cancer (PCa) tissue biopsy is the most accurate predictor of disease aggressiveness and an important measure to guide treatment strategies and patient management. The variability associated with PCa tumor sampling and the subjective determination of the GS are challenges that limit accurate diagnostication and prognostication. Thus, novel molecular signatures are needed to distinguish between indolent and aggressive forms of PCa for better patient management and outcomes. Herein, label-free LC-MS/MS proteomics is used to profile the proteome of 50 PCa tissues spanning five grade groups (n = 10 per group) relative to tissues from individuals with benign prostatic hyperplasia (BPH). Over 2000 proteins are identified albeit at different levels between and within the patient groups, revealing biological processes associated with specific grades. A panel of 11 prostate-derived proteins including IGKV3D-20, RNASET2, TACC2, ANXA7, LMOD1, PRCP, GYG1, NDUFV1, H1FX, APOBEC3C, and CTSZ display the potential to stratify patients from low and high PCa grade groups. Parallel reaction monitoring of the same sample cohort validate the differential expression of LMOD1, GYG1, IGKV3D-20, and RNASET2. The four proteins associated with low and high PCa grades reported here warrant further exploration as candidate biomarkers for PCa aggressiveness. | eng |
dc.description.sponsorship | FAPESPFundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP) [2014/06863-3, 2018/18257-1, 2018/15549-1, 2015/02866-0, 2017/03010-8] | |
dc.description.sponsorship | CINSW [ECF181259] | |
dc.description.sponsorship | Macquarie University Research Seeding Grant | |
dc.language.iso | eng | |
dc.publisher | WILEY | eng |
dc.relation.ispartof | Proteomics | |
dc.rights | restrictedAccess | eng |
dc.subject | biomarkers | eng |
dc.subject | gleason score | eng |
dc.subject | mass spectrometry | eng |
dc.subject | prostate cancer | eng |
dc.subject | proteome | eng |
dc.subject | proteomics | eng |
dc.subject.other | integrative analysis | eng |
dc.subject.other | gene | eng |
dc.subject.other | biomarkers | eng |
dc.subject.other | carcinoma | eng |
dc.subject.other | bone | eng |
dc.subject.other | identification | eng |
dc.subject.other | metastasis | eng |
dc.subject.other | apobec3b | eng |
dc.title | Tissue Proteome Signatures Associated with Five Grades of Prostate Cancer and Benign Prostatic Hyperplasia | eng |
dc.type | article | eng |
dc.rights.holder | Copyright WILEY | eng |
dc.identifier.doi | 10.1002/pmic.201900174 | |
dc.identifier.pmid | 31576646 | |
dc.subject.wos | Biochemical Research Methods | eng |
dc.subject.wos | Biochemistry & Molecular Biology | eng |
dc.type.category | original article | eng |
dc.type.version | publishedVersion | eng |
hcfmusp.author.external | KAWAHARA, Rebeca:Univ Sao Paulo, Dept Parasitol, Inst Ciencias Biomed, BR-05508000 Sao Paulo, Brazil; Macquarie Univ, Dept Mol Sci, Sydney, NSW 2109, Australia | |
hcfmusp.author.external | NOGUEIRA, Fabio C. S.:Univ Fed Rio De Janeiro, Dept Bioquim, Inst Quim, BR-21941909 Rio De Janeiro, Brazil | |
hcfmusp.author.external | DOMONT, Gilberto B.:Univ Fed Rio De Janeiro, Dept Bioquim, Inst Quim, BR-21941909 Rio De Janeiro, Brazil | |
hcfmusp.author.external | THAYSEN-ANDERSEN, Morten:Macquarie Univ, Dept Mol Sci, Sydney, NSW 2109, Australia | |
hcfmusp.author.external | PALMISANO, Giuseppe:Univ Sao Paulo, Dept Parasitol, Inst Ciencias Biomed, BR-05508000 Sao Paulo, Brazil | |
hcfmusp.description.articlenumber | 1900174 | |
hcfmusp.description.issue | 21-22 | |
hcfmusp.description.issue | Special Issue | |
hcfmusp.description.volume | 19 | |
hcfmusp.origem | WOS | |
hcfmusp.origem.id | WOS:000491105000001 | |
hcfmusp.origem.id | 2-s2.0-85074340969 | |
hcfmusp.publisher.city | HOBOKEN | eng |
hcfmusp.publisher.country | USA | eng |
hcfmusp.relation.reference | Acquati F, 2011, ONCOTARGET, V2, P477 | eng |
hcfmusp.relation.reference | Akkari L, 2014, GENE DEV, V28, P2134, DOI 10.1101/gad.249599.114 | eng |
hcfmusp.relation.reference | Burns MB, 2013, NAT GENET, V45, P977, DOI 10.1038/ng.2701 | eng |
hcfmusp.relation.reference | Burns MB, 2013, NATURE, V494, P366, DOI 10.1038/nature11881 | eng |
hcfmusp.relation.reference | Chandran UR, 2007, BMC CANCER, V7, DOI 10.1186/1471-2407-7-64 | eng |
hcfmusp.relation.reference | Chen N, 2016, CHINESE J CANCER RES, V28, P58, DOI 10.3978/j.issn.1000-9604.2016.02.04 | eng |
hcfmusp.relation.reference | Chiva C, 2017, J PROTEOME RES, V16, P1376, DOI 10.1021/acs.jproteome.6b00115 | eng |
hcfmusp.relation.reference | Cox J, 2014, MOL CELL PROTEOMICS, V13, P2513, DOI 10.1074/mcp.M113.031591 | eng |
hcfmusp.relation.reference | Cox J, 2011, J PROTEOME RES, V10, P1794, DOI 10.1021/pr101065j | eng |
hcfmusp.relation.reference | Cox J, 2008, NAT BIOTECHNOL, V26, P1367, DOI 10.1038/nbt.1511 | eng |
hcfmusp.relation.reference | Cyll K, 2017, BRIT J CANCER, V117, P367, DOI 10.1038/bjc.2017.171 | eng |
hcfmusp.relation.reference | de la Fouchardiere C, 2003, NETH J MED, V61, P347 | eng |
hcfmusp.relation.reference | Ellinger J, 2017, CLIN GENITOURIN CANC, V15, pE551, DOI 10.1016/j.clgc.2016.11.010 | eng |
hcfmusp.relation.reference | Epstein JI, 2016, AM J SURG PATHOL, V40, P244, DOI 10.1097/PAS.0000000000000530 | eng |
hcfmusp.relation.reference | Flores-Morales A, 2017, FRONT ONCOL, V7, DOI 10.3389/fonc.2017.00267 | eng |
hcfmusp.relation.reference | Gartrell BA, 2015, EUR UROL, V68, P850, DOI 10.1016/j.eururo.2015.06.039 | eng |
hcfmusp.relation.reference | Goldstein B., 2017, LUNG CANC INT, V2017, DOI 10.1155/2017/6914976 | eng |
hcfmusp.relation.reference | Gordetsky J, 2016, DIAGN PATHOL, V11, DOI 10.1186/s13000-016-0478-2 | eng |
hcfmusp.relation.reference | Guo T, 2018, LIFE SCI ALLIANCE, V1, DOI 10.26508/lsa.201800042 | eng |
hcfmusp.relation.reference | Guo XQ, 2015, CLIN CANCER RES, V21, P3501, DOI 10.1158/1078-0432.CCR-14-3141 | eng |
hcfmusp.relation.reference | Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211 | eng |
hcfmusp.relation.reference | Humphrey PA, 2004, MODERN PATHOL, V17, P292, DOI 10.1038/modpathol.3800054 | eng |
hcfmusp.relation.reference | Iglesias-Gato D, 2016, EUR UROL, V69, P942, DOI 10.1016/j.eururo.2015.10.053 | eng |
hcfmusp.relation.reference | Intasqui P, 2018, EXPERT REV PROTEOMIC, V15, P65, DOI 10.1080/14789450.2018.1417846 | eng |
hcfmusp.relation.reference | Jia XW, 2016, PROTEOMICS, V16, P2989, DOI 10.1002/pmic.201500506 | eng |
hcfmusp.relation.reference | Karpievitch Y, 2009, BIOINFORMATICS, V25, P2028, DOI 10.1093/bioinformatics/btp362 | eng |
hcfmusp.relation.reference | Kawahara Rebeca, 2018, Oncotarget, V9, P33077, DOI 10.18632/oncotarget.26005 | eng |
hcfmusp.relation.reference | Kawahara R, 2015, ONCOTARGET, V6, P43635, DOI 10.18632/oncotarget.6018 | eng |
hcfmusp.relation.reference | Liu FZ, 2015, PROSTATE, V75, P370, DOI 10.1002/pros.22923 | eng |
hcfmusp.relation.reference | Liu YS, 2014, MOL CELL PROTEOMICS, V13, P1753, DOI 10.1074/mcp.M114.038273 | eng |
hcfmusp.relation.reference | MacLean B, 2010, BIOINFORMATICS, V26, P966, DOI 10.1093/bioinformatics/btq054 | eng |
hcfmusp.relation.reference | Malati T, 2006, INDIAN J CLIN BIOCHE, V21, P34, DOI 10.1007/BF02913064 | eng |
hcfmusp.relation.reference | Mantsiou A, 2018, EXPERT REV PROTEOMIC, V15, P593, DOI 10.1080/14789450.2018.1491796 | eng |
hcfmusp.relation.reference | Mason MD, 2002, CRIT REV ONCOL HEMAT, V41, P11, DOI 10.1016/S1040-8428(01)00171-8 | eng |
hcfmusp.relation.reference | Michalski A, 2011, J PROTEOME RES, V10, P1785, DOI 10.1021/pr101060v | eng |
hcfmusp.relation.reference | Msaouel P, 2008, BEST PRACT RES CL EN, V22, P341, DOI 10.1016/j.beem.2008.01.011 | eng |
hcfmusp.relation.reference | Mundy GR, 2002, NAT REV CANCER, V2, P584, DOI 10.1038/nrc867 | eng |
hcfmusp.relation.reference | Perez-Riverol Y, 2019, NUCLEIC ACIDS RES, V47, pD442, DOI 10.1093/nar/gky1106 | eng |
hcfmusp.relation.reference | Peterson AC, 2012, MOL CELL PROTEOMICS, V11, P1475, DOI 10.1074/mcp.O112.020131 | eng |
hcfmusp.relation.reference | Pierorazio PM, 2013, BJU INT, V111, P753, DOI 10.1111/j.1464-410X.2012.11611.x | eng |
hcfmusp.relation.reference | Prensner JR, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003180 | eng |
hcfmusp.relation.reference | Ruppender N, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0130565 | eng |
hcfmusp.relation.reference | Shipitsin M, 2014, BRIT J CANCER, V111, P1201, DOI 10.1038/bjc.2014.396 | eng |
hcfmusp.relation.reference | Siegel RL, 2017, CA-CANCER J CLIN, V67, P7, DOI 10.3322/caac.21387 | eng |
hcfmusp.relation.reference | Srivastava M, 2001, P NATL ACAD SCI USA, V98, P4575, DOI 10.1073/pnas.071055798 | eng |
hcfmusp.relation.reference | Takayama KI, 2012, MOL ENDOCRINOL, V26, P748, DOI 10.1210/me.2011-1242 | eng |
hcfmusp.relation.reference | Tanase CP, 2017, ONCOTARGET, V8, P18497, DOI 10.18632/oncotarget.14501 | eng |
hcfmusp.relation.reference | Turiak L, 2019, J PROTEOMICS, V197, P82, DOI 10.1016/j.jprot.2018.11.009 | eng |
hcfmusp.relation.reference | Wang J, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024967 | eng |
hcfmusp.relation.reference | Warneboldt J, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-388 | eng |
hcfmusp.relation.reference | Xia JG, 2015, NUCLEIC ACIDS RES, V43, pW251, DOI 10.1093/nar/gkv380 | eng |
hcfmusp.relation.reference | Yu YP, 2004, J CLIN ONCOL, V22, P2790, DOI 10.1200/JCO.2004.05.158 | eng |
dc.description.index | MEDLINE | eng |
dc.identifier.eissn | 1615-9861 | |
hcfmusp.citation.scopus | 17 | - |
hcfmusp.scopus.lastupdate | 2024-03-29 | - |
Appears in Collections: | Artigos e Materiais de Revistas Científicas - FM/MCG Artigos e Materiais de Revistas Científicas - LIM/55 Artigos e Materiais de Revistas Científicas - ODS/03 |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
art_KAWAHARA_Tissue_Proteome_Signatures_Associated_with_Five_Grades_of_2019.PDF Restricted Access | publishedVersion (English) | 2.12 MB | Adobe PDF | View/Open Request a copy |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.